Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -581,599 | -366,252 | -153,610 | -650,175 | 377,661 |
| Depreciation Amortization | 19,479 | 19,259 | 19,837 | 24,172 | 17,953 |
| Accounts receivable | 25,000 | 175,000 | -200,000 | 305 | -161 |
| Other Working Capital | 71,882 | 156,270 | -193,585 | 19,845 | 26,859 |
| Other Operating Activity | 120,224 | -127,051 | 266,983 | 110,112 | 116,660 |
| Operating Cash Flow | $-345,014 | $-142,774 | $-260,375 | $-495,741 | $538,972 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 3,107 | -255,397 | 386,617 | -221,467 | -953,725 |
| PPE Investments | -914 | -1,901 | -9,470 | -37,188 | -81,705 |
| Purchase Of Investment | -9,700 | -23,183 | N/A | N/A | N/A |
| Sale Of Investment | 702 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -25,000 | 0 | -2,500 | 0 | 0 |
| Investing Cash Flow | $-31,805 | $-280,481 | $374,647 | $-258,655 | $-1,035,430 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 426,026 | 331,984 | 62,664 | 38,592 | 250,945 |
| Financing Cash Flow | $426,026 | $331,984 | $62,664 | $38,592 | $250,945 |
| Exchange Rate Effect | 95 | -21 | 73 | -80 | -11 |
| Beginning Cash Position | 309,776 | 401,068 | 224,060 | 939,944 | 1,185,468 |
| End Cash Position | 359,078 | 309,776 | 401,068 | 224,060 | 939,944 |
| Net Cash Flow | $49,302 | $-91,292 | $177,008 | $-715,884 | $-245,524 |
| Free Cash Flow | |||||
| Operating Cash Flow | -345,014 | -142,774 | -260,375 | -495,741 | 538,972 |
| Capital Expenditure | -914 | -1,901 | -9,470 | -37,188 | -81,705 |
| Free Cash Flow | -345,928 | -144,675 | -269,845 | -532,929 | 457,267 |